New pill for Hard-to-Treat cancers enters early human testing

NCT ID NCT06625515

Terminated Disease control Sponsor: Accent Therapeutics Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 19 times

Summary

This early-stage study tested an experimental pill called ATX-559 in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

NEXT Oncology

San Antonio, Texas, 78229, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Stephenson Cancer Center at OU Medicine

Oklahoma City, Oklahoma, 73104, United States
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Colorado Cancer Center - Anschutz Medical Campus,

Aurora, Colorado, 80045, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS BREAST CANCER RECURRENT COLON CANCER COLON CANCER COLORECTAL CANCER METASTATIC ENDOMETRIAL CANCER ENDOMETRIAL CANCER RECTAL ADENOCARCINOMA